Item 1A. Risk Factors. In addition to the other information set forth in this report, you should carefully consider the factors discussed below and in Part I, Item 1A. Risk Factors of our 2024 Annual Report, which could materially affect our business, financial condition or future results. Failure to meet Nasdaqs continued listing requirements could result in the delisting of our common shares, negatively impact the price of our common shares and negatively impact our ability to raise additional capital. On November 25, 2024, we received a deficiency letter, or the letter (the Nasdaq Letter, Letter), from the Listing Qualifications Department of The Nasdaq Stock Market LLC, notifying us that we are not in compliance with the Stockholders Equity Requirement, which requires us to maintain a minimum of $2.5 million in stockholders equity, nor we are in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. On January 6, 2025, we submitted a plan to regain compliance, or the compliance (the Compliance Plan. Plan). Based on the Compliance Plan, Nasdaq has determined to grant us with an extension of time to regain compliance with the Stockholders Equity Requirement until May 24, 2025. If we fail to evidence compliance by On May 7, 2025, the required deadline, we may be subject to delisting. At that time, we may appeal Staffs determination to Company received a Hearings Panel. We intend to take all reasonable measures available to regain letter from Nasdaq, determining that the Company has regained compliance with Listing Rule 5550(b)(2), due to the fact that for the 10 consecutive business days from April 22, 2025 through May 6, 2025, the market value of the Companys listed securities was $35 million or greater, satisfying the requirement under Rule 5550(b)(2). Accordingly, the Nasdaq Listing Rules Company has regained compliance with the Shareholders Equity Requirement and remain listed remains in good standing on Nasdaq. However, there can be no assurance The Nasdaq Capital Market. We cannot guarantee that we will ultimately regain compliance continue to comply with all applicable requirements for continued listing. Neither the Nasdaq Letter nor our noncompliance have an immediate effect on the listing or trading of our common shares, which will continue Shareholders Equity Requirement. If we fail to trade on The Nasdaq Capital Market under comply with the symbol PLUR. If, for any reason, Nasdaq should Shareholders Equity Requirement, Nasdaq could delist our common shares from trading on its exchange and we are unable to obtain listing on another national securities exchange or take action to restore our compliance with the Nasdaq continued listing requirements, a reduction in some or all of the following may occur, each of which we and our shareholders could have a incur material adverse effect consequences, including a negative impact on our shareholders: The liquidity of liquidity, our common shares; the market price of our common shares; our shareholders ability to obtain financing for the continuation of our operations; the number of institutional sell shares and general investors that will consider investing in our common shares; the number of investors in general that will consider investing in our common shares; the number of market makers in our common shares; the availability of information concerning the trading prices and volume of our common shares; and the number of broker-dealers willing ability to execute trades in shares of our common shares raise capital 31 Our principal research, development and manufacturing facilities are located in Haifa, Israel and military conditions in Israel, including armed conflicts between Israel and Hamas, Hezbollah and other terrorist organizations from the Gaza Strip and Lebanon, may cause interruption or suspension of our business operations without warning. Our principal RD and manufacturing facilities are located in Haifa, Israel, thus, political, economic, and military conditions in Israel, and in particular, conflicts between involving Israel and Hamas, Hezbollah in Lebanon, Iran and other Arab terrorists groups, may directly affect our business. As of today, there has been no material impact on our operations. According to the recent guidelines of the Israeli government, the Companys offices in Haifa are open and functioning, however, if a war will escalate and expand, this situation may change and the Israeli government may impose certain restrictions on movement and travel, which will affect our management and employees ability to effectively perform their daily tasks, and may result in disruptions and delays in some of our projects. Any hostilities involving Israel, terrorist activities, political instability or violence in the region, or the interruption or curtailment of trade or transport between Israel and its trading partners could make it more difficult for us to raise capital, if needed in the future, and adversely affect our operations and results of operations and the market price of our common shares. In addition, to the extent the IIA no longer makes grants similar to those we have received in the past, it could adversely affect our financial results. 26 Furthermore, certain of our employees may be obligated to perform annual reserve duty in the Israel Defense Forces and are subject to being called up for active military duty at any time. Many Israeli citizens who have served in the army are required to perform reserve duty until they reach the age of 40 or older, depending upon the nature of their military service. Currently, one Currently none of our employees have has been called up for active military reserve duty. Wars implications, including but not only wars economic implications, on the Companys business and operations and on Israels economy in general is difficult to predict. Such events may be intertwined with wider macroeconomic indications of a deterioration of Israels economic standing, for instance, a downgrade in Israels credit rating by rating agencies, which may have a material adverse effect on the Company and its ability to effectively conduct its operations. In addition, Israeli-based companies and companies doing business with Israel, have been the subject of an economic boycott by members of the Arab League and certain other predominantly Muslim countries since Israels establishment. Although Israel has entered into various agreements with certain Arab countries and the Palestinian Authority, and various declarations have been signed in connection with efforts to resolve some of the economic and political problems in the Middle East, we cannot predict whether or in what manner these problems will be resolved. Wars and acts of terrorism have resulted in significant damage to the Israeli economy, including reducing the level of foreign and local investment. Failure to reach an agreement with the EIB about the repayment of the EIB Loan could adversely affect our financial condition and liquidity. On April 30, 2020, we and our subsidiaries, Pluri Biotech Ltd. and Pluristem GmbH, entered into the EIB Finance Agreement for a loan in the amount of up to 50 million in the aggregate, subject to certain milestones being reached, receivable in three tranches. During June 2021, we received the first tranche in the amount of 20 million. The amount received is due to be repaid on June 1, 2026, and bears annual interest of 4% to be paid together with the principal amount of the loan. As of March 31, 2025, the interest accrued was in the amount of approximately 3.06 million. In addition to the interest payable, the EIB is also entitled to royalty payments, pro-rated to the amount disbursed from the EIB Loan, on our consolidated revenues beginning in the fiscal year 2024 up to and including its fiscal year 2030, in an amount equal to up to 2.3% of our consolidated revenues below $350 million, 1.2% of our consolidated revenues between $350 million and $500 million and 0.2% of our consolidated revenues exceeding $500 million. As of March 31, 2025, we had an accrued royalty in the amount of $8 thousand. We are currently in discussions with the EIB regarding a potential restructuring of the terms of the EIB Loan. Such discussions are currently focused on the new terms of the EIB Loan, including an extension of the current maturity date of the EIB Loan. The Company is expecting to finalize such discussions by the end of June 2025; however, there is no certainty that such restructuring will be achieved on the expected timeline or at all. If we fail to reach an agreement with the EIB about the repayment of the EIB Loan, or if we are unable to repay the EIB Loan when due, our financial condition and liquidity would be materially affected and could impact our ability to continue as a going concern.